Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ABOS Acumen Pharmaceuticals	$1.36 -3.5%	$1.33	$0.86 ▼ $3.36	$85.41M	0.14	255,601 shs	74,438 shs
BNTC Benitec Biopharma	$12.70 -1.4%	$12.65	$8.06 ▼ $17.15	$338.11M	0.4	43,661 shs	17,239 shs
FDMT 4D Molecular Therapeutics	$6.85	$4.87	$2.23 ▼ $17.41	$319.91M	2.83	2.56 million shs	380,554 shs
INBX Inhibrx Biosciences	$24.16 -1.0%	$20.10	$10.81 ▼ $25.29	$353.59M	0.24	100,805 shs	143,209 shs

These 7 Stocks Will Be Magnificent in 2025

Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2025. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ABOS Acumen Pharmaceuticals	-3.55%	-2.86%	-18.56%	+33.33%	-52.28%
BNTC Benitec Biopharma	-1.40%	+0.32%	+12.79%	-3.71%	+41.74%
FDMT 4D Molecular Therapeutics	0.00%	-3.52%	+52.22%	+96.28%	-54.90%
INBX Inhibrx Biosciences	-1.02%	+0.92%	+5.69%	+87.87%	+85.13%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
ABOS Acumen Pharmaceuticals	3.0411 of 5 stars	3.5	5.0	0.0	1.4	1.7	0.6
BNTC Benitec Biopharma	1.5711 of 5 stars	3.6	1.0	0.0	2.0	0.8	0.0
FDMT 4D Molecular Therapeutics	2.0938 of 5 stars	3.3	2.0	0.0	1.6	1.7	0.6
INBX Inhibrx Biosciences	1.9252 of 5 stars	0.0	3.0	4.6	2.6	2.5	0.0

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ABOS Acumen Pharmaceuticals	3.00	Buy	$6.33	365.69% Upside
BNTC Benitec Biopharma	3.13	Buy	$26.00	104.72% Upside
FDMT 4D Molecular Therapeutics	2.64	Moderate Buy	$30.40	343.80% Upside
INBX Inhibrx Biosciences	2.00	Hold	N/A	N/A

Current Analyst Ratings Breakdown

Latest ABOS, BNTC, FDMT, and INBX Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/14/2025	FDMT 4D Molecular Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Sell (D-) ➝ Sell (D-)
8/12/2025	FDMT 4D Molecular Therapeutics	Roth Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$44.00 ➝ $38.00
8/12/2025	FDMT 4D Molecular Therapeutics	Chardan Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$25.00
8/1/2025	FDMT 4D Molecular Therapeutics	Chardan Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$25.00
7/29/2025	FDMT 4D Molecular Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Sell (D-) ➝ Sell (D-)
7/12/2025	FDMT 4D Molecular Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Sell (E+) ➝ Sell (D-)
7/7/2025	BNTC Benitec Biopharma	TD Cowen Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy
7/3/2025	FDMT 4D Molecular Therapeutics	Chardan Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$25.00
6/27/2025	FDMT 4D Molecular Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Sell (D-) ➝ Sell (E+)
6/17/2025	ABOS Acumen Pharmaceuticals	Citigroup Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$4.00
6/11/2025	FDMT 4D Molecular Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Sell (E+) ➝ Sell (D-)

(Data available from 8/22/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ABOS Acumen Pharmaceuticals	N/A	N/A	N/A	N/A	$1.93 per share	N/A
BNTC Benitec Biopharma	$80K	4,167.19	N/A	N/A	$4.68 per share	2.71
FDMT 4D Molecular Therapeutics	$40K	7,997.38	N/A	N/A	$9.01 per share	0.76
INBX Inhibrx Biosciences	$200K	1,749.18	$115.05 per share	0.21	$4.73 per share	5.11

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ABOS Acumen Pharmaceuticals	-$102.33M	-$2.28	N/A	N/A	N/A	N/A	-81.39%	-61.96%	N/A
BNTC Benitec Biopharma	-$21.75M	-$1.51	N/A	N/A	N/A	N/A	-38.26%	-35.71%	9/25/2025 (Estimated)
FDMT 4D Molecular Therapeutics	-$160.87M	-$3.53	N/A	N/A	N/A	-594,375.81%	-40.15%	-36.43%	N/A
INBX Inhibrx Biosciences	$1.69B	-$10.58	N/A	N/A	N/A	N/A	-137.83%	-76.31%	N/A

Latest ABOS, BNTC, FDMT, and INBX Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/13/2025	Q2 2025	INBX Inhibrx Biosciences	-$2.92	-$1.85	+$1.07	-$1.85	N/A	$1.30 million
8/12/2025	Q2 2025	ABOS Acumen Pharmaceuticals	-$0.54	-$0.68	-$0.14	-$0.68	N/A	N/A
8/11/2025	Q2 2025	FDMT 4D Molecular Therapeutics	-$0.88	-$0.98	-$0.10	-$0.98	$0.52 million	$0.01 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
ABOS Acumen Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
BNTC Benitec Biopharma	N/A	N/A	N/A	N/A	N/A
FDMT 4D Molecular Therapeutics	N/A	N/A	N/A	N/A	N/A
INBX Inhibrx Biosciences	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ABOS Acumen Pharmaceuticals	0.26	5.97	5.97
BNTC Benitec Biopharma	0.01	14.80	14.80
FDMT 4D Molecular Therapeutics	N/A	8.75	8.75
INBX Inhibrx Biosciences	1.45	4.98	4.98

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ABOS Acumen Pharmaceuticals	71.01%
BNTC Benitec Biopharma	52.19%
FDMT 4D Molecular Therapeutics	99.27%
INBX Inhibrx Biosciences	82.46%

Insider Ownership

Company	Insider Ownership
ABOS Acumen Pharmaceuticals	9.30%
BNTC Benitec Biopharma	1.30%
FDMT 4D Molecular Therapeutics	9.60%
INBX Inhibrx Biosciences	17.09%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ABOS Acumen Pharmaceuticals	20	60.57 million	54.94 million	Optionable
BNTC Benitec Biopharma	20	26.25 million	25.91 million	No Data
FDMT 4D Molecular Therapeutics	120	46.70 million	42.22 million	Optionable
INBX Inhibrx Biosciences	166	14.48 million	12.01 million	Optionable

ABOS, BNTC, FDMT, and INBX Headlines

Recent News About These Companies

HighTower Advisors LLC Acquires 90,002 Shares of Inhibrx Biosciences, Inc. (NASDAQ:INBX)

August 19 at 4:30 AM | marketbeat.com

Inhibrx Biosciences (NASDAQ:INBX) Upgraded by Wall Street Zen to "Hold" Rating

August 19 at 2:47 AM | americanbankingnews.com

Inhibrx Biosciences (NASDAQ:INBX) Upgraded by Wall Street Zen to Hold Rating

August 18, 2025 | marketbeat.com

Inhibrx Biosciences (NASDAQ:INBX) Releases Earnings Results, Beats Estimates By $1.07 EPS

August 15, 2025 | marketbeat.com

Inhibrx Biosciences, Inc.: Inhibrx Reports Second Quarter 2025 Financial Results

August 14, 2025 | finanznachrichten.de

XTX Topco Ltd Makes New Investment in Inhibrx Biosciences, Inc. (NASDAQ:INBX)

August 14, 2025 | marketbeat.com

Inhibrx Reports Second Quarter 2025 Financial Results

August 13, 2025 | prnewswire.com

Inhibrx Biosciences (INBX) Projected to Post Quarterly Earnings on Tuesday

August 11, 2025 | americanbankingnews.com

Inhibrx Biosciences (INBX) Projected to Post Earnings on Tuesday

August 6, 2025 | marketbeat.com

Inhibrx Biosciences Advances HexAgon-HN Study for Head, Neck Cancer

July 29, 2025 | msn.com

Tabor Asset Management LP Invests $506,000 in Inhibrx Biosciences, Inc. (NASDAQ:INBX)

July 22, 2025 | marketbeat.com

Inhibrx Biosciences: Seeing Soon If The Momentum Is Just Hype

July 18, 2025 | seekingalpha.com

Noteworthy Tuesday Option Activity: INBX, ODP, AZO | Nasdaq

July 10, 2025 | nasdaq.com

INBX - Inhibrx Biosciences Inc Executives - Morningstar

July 2, 2025 | morningstar.comM

Inhibrx Biosciences, Inc. (INBX) - Yahoo Finance

June 28, 2025 | finance.yahoo.com

Inhibrx Biosciences Inc (INBX) - Investing.com

June 25, 2025 | investing.com

Inhibrx Biosciences, Inc.: Inhibrx Reports First Quarter 2025 Financial Results

May 15, 2025 | finanznachrichten.de

Inhibrx Reports First Quarter 2025 Financial Results

May 14, 2025 | prnewswire.com

Inhibrx Biosciences reshuffles leadership, appoints new CSO and President

April 3, 2025 | investing.com

Inhibrx announces leadership changes as co-founder departs

April 2, 2025 | thepharmaletter.comT

Inhibrx Biosciences Announces Departure of CSO and Appointments of New CSO and President

April 1, 2025 | prnewswire.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

ABOS, BNTC, FDMT, and INBX Company Descriptions

Acumen Pharmaceuticals NASDAQ:ABOS

$1.36 -0.05 (-3.55%)

Closing price 08/21/2025 04:00 PM Eastern

Extended Trading

$1.38 +0.02 (+1.84%)

As of 08/21/2025 07:34 PM Eastern

Acumen Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops targeted therapies for the treatment of Alzheimer's disease. The company focuses on advancing a targeted immunotherapy drug candidate sabirnetug (ACU193), a recombinant humanized immunoglobulin gamma 2 that completed Phase I clinical trial to target soluble amyloid-beta oligomers. The company has a license agreement with Lonza Sales AG to manufacture and commercialize sabirnetug; and a collaboration and license agreement with Halozyme, Inc. for the development of a subcutaneous formulation of sabirnetug. Acumen Pharmaceuticals, Inc. was incorporated in 1996 and is headquartered in Charlottesville, Virginia.

Benitec Biopharma NASDAQ:BNTC

$12.70 -0.18 (-1.40%)

Closing price 08/21/2025 04:00 PM Eastern

Extended Trading

$12.70 0.00 (0.00%)

As of 08/21/2025 05:30 PM Eastern

Benitec Biopharma Inc., a clinical-stage biotechnology company, focuses on the development of novel genetic medicines. The company develops DNA-directed RNA interference-based therapeutics for chronic and life-threatening human conditions. It is developing BB-301, an adeno-associated virus based gene therapy agent for treating oculopharyngeal muscular dystrophy. The company was incorporated in 1995 and is headquartered in Hayward, California.

4D Molecular Therapeutics NASDAQ:FDMT

$6.85 0.00 (0.00%)

Closing price 08/21/2025 04:00 PM Eastern

Extended Trading

$6.85 0.00 (0.00%)

As of 08/21/2025 07:42 PM Eastern

4D Molecular Therapeutics, Inc., a clinical-stage biotherapeutics company, develops genetic medicines using its therapeutic vector evolution platform in the Netherland and the United States. The company develops a portfolio of genetic medicine product candidates focuses in three therapeutic areas for ophthalmology, cardiology, and pulmonology. Its product pipeline includes 4D-150, which is in phase 1/2 clinical trial for the treatment of wet age-related macular degeneration; and is in phase 1/2 clinical trial for the treatment of diabetic macular edema. The company develops 4D-125, which is in phase 1/2 clinical trial for the treatment of x-linked retinitis pigmentosa; 4D-110, which is in phase 1/2 clinical trial for the treatment of choroideremia; 4D-710, which is in phase 1/2 clinical trial for the treatment cystic fibrosis lung disease; and 4D-310 to treat fabry disease cardiomyopathy and is in phase 1/2 clinical trial. In addition, its product candidates comprises 4D-175, which is in pre-clinical development for the treatment for geographic trophy; and 4D-725 to treat alpha-1 antitrypsin deficiency lung disease and is in pre-clinical development. The company has collaboration and licensing agreements with Arbor Biotechnologies, Inc.; Astellas Gene Therapies, Inc; uniQure biopharma B.V.; and Cystic Fibrosis Foundation. 4D Molecular Therapeutics, Inc. was founded in 2013 and is headquartered in Emeryville, California.

Inhibrx Biosciences NASDAQ:INBX

$24.16 -0.25 (-1.02%)

Closing price 08/21/2025 04:00 PM Eastern

Extended Trading

$24.16 0.00 (0.00%)

As of 08/21/2025 04:20 PM Eastern

Inhibrx, Inc., a clinical-stage biopharmaceutical company, develops a pipeline of novel biologic therapeutic candidates. The company's therapeutic candidate includes INBRX-101, an alpha-1 antitrypsin (AAT)-Fc fusion protein therapeutic candidate, which is in Phase 1 clinical trials for use in the treatment of patients with AAT deficiency. It also develops INBRX-109, a tetravalent therapeutic candidate targeting death receptor 5, which is in Phase 2 clinical trials to treat cancers, such as chondrosarcoma, mesothelioma, colorectal cancer, ewing sarcoma, and pancreatic adenocarcinoma; and INBRX-106, a hexavalent agonist of OX40 for a range of oncology indications. The company has license and collaboration agreements with 2seventy bio, Inc. and Bristol-Myers Squibb Company. Inhibrx, Inc. was incorporated in 2009 and is headquartered in La Jolla, California.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time